Moleculin Biotech
MBRX
MBRX
22 hedge funds and large institutions have $3.17M invested in Moleculin Biotech in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Holders
22
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$41.4K | |
| 2 | +$15.6K | |
| 3 | +$3.38K | |
| 4 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
+$844 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$844 |
Top Sellers
| 1 | -$21K | |
| 2 | -$12K | |
| 3 | -$6.75K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$5.07K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$3.38K |